Shire PLC (SHPG)

190.68
NASDAQ : Health Care
Prev Close 191.67
Day Low/High 189.36 / 193.72
52 Wk Low/High 147.60 / 237.76
Avg Volume 2.11M
Exchange NASDAQ
Shares Outstanding 300.07M
Market Cap 57.51B
EPS 6.60
P/E Ratio 52.08
Div & Yield 0.28 (0.10%)

Latest News

9 Stocks Smart Investors Put Their Money in Last Quarter

9 Stocks Smart Investors Put Their Money in Last Quarter

Hedge fund managers continue to flee stocks in the second quarter, but the smart money eyed several potential opportunities, including Charter Communications and Morgan Stanley.

Utilities Need to Get Their Act Together

If they're underperforming, they're typically a precursor to a market correction.

Radius Health, Subject of Takeover Talk, Rises Again

Radius Health, Subject of Takeover Talk, Rises Again

The drug maker with an osteoporosis product in development has been speculated about as a consolidation candidate.

VONVENDI, The First And Only Recombinant Treatment For Adults Affected By Von Willebrand Disease, Launches In The U.S.

VONVENDI, The First And Only Recombinant Treatment For Adults Affected By Von Willebrand Disease, Launches In The U.S.

VONVENDI [von Willebrand factor (Recombinant)] is a significant advancement for the treatment of adults with von Willebrand disease (VWD)

Analysts' Actions -- Tableau, Garmin, Pioneer, Shire and More

Analysts' Actions -- Tableau, Garmin, Pioneer, Shire and More

Here are Thursday's top research calls, including downgrades for Tableau Data, Garmin and Pioneer Natural Resources, and an upgrade for Chegg.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMED, CGNX, CHGG, ENSG, FOMX, GATX, MIC, RPAI, SBRA, TDC, TSRI, TX, TZOO, WNRL Downgrades: AMIC, FE, SHPG, SOHU, TCBI Initiations: GPP Read on to get TheStreet Quant Ratings' detailed report:

Today's Unusual Social Activity Stock: Shire (SHPG)

Today's Unusual Social Activity Stock: Shire (SHPG)

Trade-Ideas LLC identified Shire (SHPG) as an unusual social activity candidate

Shire’s Share Surge on Strong Second-Quarter Results

Shire’s Share Surge on Strong Second-Quarter Results

The Ireland-based biopharma company lifts its forecast for Baxalta-related cost savings.

What to Expect When Shire (SHPG) Reports Q2 Earnings Tomorrow

What to Expect When Shire (SHPG) Reports Q2 Earnings Tomorrow

Shire (SHPG) is slated to report fiscal 2016 second quarter earnings and revenue before tomorrow's market open.

Shire Announces FDA Approval Of Adynovate With BAXJECT III Reconstitution System

Shire Announces FDA Approval Of Adynovate With BAXJECT III Reconstitution System

New system reduces number of steps in the treatment process for hemophilia A patients on ADYNOVATE [Antihemophilic Factor, (Recombinant), PEGylated]

Today's Pre-Market Trading Very Positive For Shire (SHPG)

Today's Pre-Market Trading Very Positive For Shire (SHPG)

Trade-Ideas LLC identified Shire (SHPG) as a pre-market leader candidate

3 Stocks Pushing The Health Care Sector Downward

3 Stocks Pushing The Health Care Sector Downward

TheStreet highlights 3 stocks pushing the health care sector lower today.

ADYNOVATE Phase 3 Efficacy And Safety Data In Children To Be Showcased During International Congress Of The World Federation Of Hemophilia

ADYNOVATE Phase 3 Efficacy And Safety Data In Children To Be Showcased During International Congress Of The World Federation Of Hemophilia

Shire committed to advancing treatment and raising standards of care for hemophilia patients around the world

3 Stocks Pushing The Drugs Industry Downward

3 Stocks Pushing The Drugs Industry Downward

TheStreet highlights 3 stocks pushing the drugs industry lower today.

Shire Reinforces Commitment In Hematology With Robust Data Presented At International Congress Of The World Federation Of Hemophilia

Shire Reinforces Commitment In Hematology With Robust Data Presented At International Congress Of The World Federation Of Hemophilia

More than 40 presentations and sessions feature broad pipeline and proven factor replacement portfolio, with new innovation on outcomes, safety and efficacy measures

Shire Could Divest ADHD Treatment, Other Assets, for More Upside Post-Baxalta

Shire Could Divest ADHD Treatment, Other Assets, for More Upside Post-Baxalta

At least one company follower believes the divestiture of Shire's Neurology division for as much as $13 billion would be a logical next move.

3 Drugs Stocks Dragging The Industry Down

3 Drugs Stocks Dragging The Industry Down

TheStreet highlights 3 stocks pushing the health services industry lower today.

European Markets Mixed; Retailers and Automakers Advance

European Markets Mixed; Retailers and Automakers Advance

German consumer price data confirms inflation is accelerating; automakers rise on better-than-expected earnings.

July 12 Premarket Briefing: 10 Things You Should Know

July 12 Premarket Briefing: 10 Things You Should Know

U.S. stock futures are pointing to a higher start for Wall Street on Tuesday following a record close for the S&P 500.

Pre-Market Activity Shows Gains For Shire (SHPG)

Pre-Market Activity Shows Gains For Shire (SHPG)

Trade-Ideas LLC identified Shire (SHPG) as a pre-market leader candidate

Shire’s Shares Rise on FDA Approval of Dry Eye Med

Shire’s Shares Rise on FDA Approval of Dry Eye Med

Jefferies estimates Xiidra could yield revenue of $1.5 billion within five years of its launch.

European Markets Mixed; Shire Gains on 'Blockbuster' Eye-Drop Clearance

European Markets Mixed; Shire Gains on 'Blockbuster' Eye-Drop Clearance

German consumer price data confirms inflation is accelerating, while in the U.K. a closely watched gauge of retail sales slows to a seven-year low.